Loading clinical trials...

Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease

Analysis for the Efficacy of Individual Treatment of Perianal Fistulizing Crohn's Disease With Ustekinumab

NCT06739278•Second Affiliated Hospital of Wenzhou Medical University

Summary

This study intends to further explore the actual efficacy of ustekinumab in the individualized treatment of anal fistula Crohn's disease.

Detailed Description

Participants in the study receive ustekinumab injections as part of routine medical care. The study just observes the efficacy retrospectively and does not interfere with treatment.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Clinical diagnosis of Perianal Fistulizing Crohn's Disease
•Receive ustekinumab therapy

Exclusion Criteria

•Ustekinumab combined with hormones, immunosuppressants, other biologics or small molecule drugs
•Combined with other autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Graves disease, etc.
•Combined with serious infectious diseases, such as active tuberculosis, EBV infection, cytomegalovirus infection, etc.
•Combined with malignant tumor
•Clinical data missing ≥30% or no follow-up

Locations (1)

The Second Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, China

Key Dates

Start Date

December 20, 2024

Primary Completion Date

December 31, 2024

Completion Date

January 31, 2025

Last Updated

December 18, 2024

Enrollment

119

ESTIMATED participants

Conditions

Crohn Disease

Contacts

Yi Jiang

CONTACT

+86-13676715543 1009419972@qq.com

Luyan Fang

CONTACT

+86 13806552632 239542008@qq.com

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

NCT07245394

Inflammatory Bowel Disease (IBD)Crohn Disease (CD)+2 more

View study

RECRUITING

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420

IBD (Inflammatory Bowel Disease)IBS - Irritable Bowel Syndrome+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 18, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Individual Treatment of Ustekinumab in Perianal Fistulizing Crohn's Disease

Inclusion Criteria

Exclusion Criteria

Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

Immunological Characteristics of Preclinical IBD

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Robotic Inflammatory Bowel Disease Development, Learning and Efficacy Study